Atlantic Research Group Forms Rare Disease Strategic Advisory Board to Accelerate Novel Medicines
August 12, 2017Atlantic Research Group forms Rare Disease Strategic Advisory Board to accelerate novel medicines. Learn about this collaboration between patient advocacy groups, government institutions, and drug developers to address challenges in rare disease.
“Rare disease studies are complex, and thus success is largely determined by uniting the right partners who will collaborate to bring a breadth of experiences and perspectives to solve these unique challenges, and generate appropriate solutions," said Paul Bishop, ARG's CEO. "We’ve carefully built relationships with key global thought leaders who have a life-long interest in accelerating rare disease drug development. By bringing in outside expert advice, the SAB will help ensure that all clinical trial management will be grounded in the latest science and best practices."
